Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report from 2021 To 2027, Application Scope, Growth Drivers, Insights, Market Report.

The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is sectioned on the basis of drug type. The market is sectioned as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the global dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are projected to hold the most lucrative share in the market. The key aspects that drive the segmental growth of the dipeptidyl peptidase 4 (DPP-4) inhibitors market include the effectiveness of the drugs. As per the NCBI NLM, the Sitagliptin and Saxagliptin drugs hold the lucrative share in the market owing to their effectiveness on the patients.

(Get 15% Discount on Buying this Report)

Get Report Sample Copy @ https://www.omrglobal.com/request-sample/dipeptidyl-peptidase-4-inhibitors-market

There has been an upsurge witnessed in the prevalence of diabetes across the globe. As per the WHO, over the last three decades there has been an upsurge in the prevalence of diabetes. As per the IDF, the cases of diabetic were nearly 463 million across the globe in 2019. The cases are projected to increase which is expected to rise to 578 million by 2030 and nearly 700 million by 2045. An increase in the prevalence of diabetes is likely to demand the proper drugs for the treatment. Thus, owing to the market is likely to witness an upsurge over the forecast period.

A Full Report of Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/dipeptidyl-peptidase-4-inhibitors-market

Market Coverage

  • Market number available for – 2019-2026
  • Base year- 2019
  • Forecast period- 2020-2026
  • Segment Covered- By Type
  • Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
  • Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others

Global Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation

By Type

  • Sitagliptin
  • Vildagliptin
  • Saxagliptin
  • Linagliptin
  • Gemigliptin
  • Anagliptin
  • Teneligliptin
  • Others

 

(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)

 

Leave a Reply

Your email address will not be published. Required fields are marked *